Zealthy Weight Loss Review: Program Model, Routing, Cost

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we break down GLP-1 programs, weight-management protocols, and the inherited factors behind every metabolic choice. Browse all Peptides & GLP-1 education

This review is editorially independent. PlexusDx holds no commercial relationship with Zealthy or its parent company, and nothing here involves affiliate links or paid placement.

Shoppers comparing telehealth weight-loss options often reach Zealthy without a clear picture of what the subscription actually delivers. This editorial review walks through Zealthy's weight-loss offering as of April 2026 — its provider model, how medication is routed, and what shapes the monthly bill — offered as fair-balance context rather than a purchase recommendation.

What you're signing up for with Zealthy

Zealthy runs on a subscription telehealth model. In practice, a licensed provider evaluates you virtually and, if you qualify, writes a prescription filled either at a retail pharmacy for an FDA-approved brand product or at a 503A compounding pharmacy for a compounded semaglutide or tirzepatide preparation. Follow-up visits continue for the life of the subscription. Current terms and pricing live on Zealthy's official website.

The intake-to-prescription pathway

Programs of this type share a common sequence: you complete an intake questionnaire covering weight, medical history, and current medications; a clinician reviews it and confirms eligibility; an approved prescription is routed to the fulfilling pharmacy; and scheduled telehealth check-ins support dose titration and side-effect management. Where Zealthy and its peers diverge is in the details — whether a physician or an NP/PA signs off, which pharmacy partner fills the order, and how the subscription tiers are built.

Retail brand versus compounded routing

One of the more consequential distinctions in this model is the fulfillment pathway. A retail route dispenses FDA-approved branded products, while a 503A compounding route dispenses compounded semaglutide or tirzepatide prepared for an individual patient. The two paths differ in oversight, availability, and cost, and which one a given prescription follows is not always obvious at signup. Confirm the pathway before committing.

What the monthly cost reflects

Zealthy publishes its own pricing, and the figure you see reflects several moving parts: the specific compound, the subscription tier, and whether the medication is branded or compounded. Across the telehealth GLP-1 market as of April 2026, monthly totals commonly land somewhere between roughly $200 and $700-plus, with wide variance. Because these numbers change often, verify the current amount on Zealthy's official website before deciding.

Evidence behind the GLP-1 class

Any credible GLP-1 program rests on the pharmacology of its underlying compounds — GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, plus the GIP/GLP-1 dual agonist tirzepatide. The trial record includes STEP (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Populations and endpoints differ across these programs, and individual outcomes vary.

The genetic layer Zealthy's intake skips

What no telehealth intake form asks about is the inherited biology sitting upstream of every GLP-1 response. Variants in FTO (fat-mass and obesity-associated), GLP1R (the GLP-1 receptor itself), MC4R (a melanocortin receptor central to satiety), and TCF7L2 (a transcription factor tied to glucose handling) describe the metabolic baseline any compound has to work within. These are pathway-level markers — they do not predict how you will respond to a particular drug, but they do map the terrain a clinician is prescribing into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The difference is upstream context: before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, MC4R, and TCF7L2 variants that shape your baseline appetite-regulation and energy-balance biology. That is the test before you invest approach, turning guesswork into an informed conversation with your provider.

Not affiliated: PlexusDx has no affiliation or commercial relationship with Zealthy or any company named in this review.

Related reading on PlexusDx: Oral Semaglutide Weight Loss, Wegovy vs Zepbound Weight Loss, Semaglutide Pills For Weight Loss, Trulicity For Weight Loss Reviews.

Disclaimer: This article is educational. PlexusDx is not affiliated with Zealthy and offers semaglutide and tirzepatide through its own Weight Management Protocols — this review simply compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Prefer to start with the biology? Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols to see the genetic context most telehealth programs leave out.

Frequently Asked Questions

Is Zealthy a legitimate weight-loss service?

Zealthy operates in the GLP-1 telehealth space as of April 2026. Legitimate programs of this kind share traits: licensed clinicians, state-licensed pharmacy partners, transparent pricing, and a clinical evaluation before any prescription. Verify credentialing and licensure directly on the brand's own site before any purchase.

How much does the Zealthy weight-loss program cost?

Zealthy posts pricing on its own website, and it changes over time. Telehealth GLP-1 programs generally run $200 to $700-plus per month as of April 2026, depending on the medication, subscription tier, and whether the fill is branded or compounded. Confirm the current figure before committing.

Who is eligible for a Zealthy weight-loss prescription?

Eligibility is determined by the reviewing clinician using your intake information — weight, medical history, and current medications. Telehealth programs generally follow indication-based criteria, and a provider may decline if a prescription is not clinically appropriate. Zealthy's own site details its current screening requirements.

How does the Precision Peptide Genetic Test relate to a Zealthy program?

It doesn't predict how any Zealthy prescription will work. The test analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 biology — upstream context that applies no matter which telehealth service ultimately writes the prescription. It is educational, not a response predictor.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.